# OncoResponse

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oncoresponse

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.oncoresponseinc.com
- Total disclosed funding: $90M
- Latest round: Series C (Mar 17, 2021)
- Investors on record: 15

## About

OncoResponse, Inc. is a US-based biotechnology firm focused on developing innovative cancer immunotherapies by harnessing human antibodies to target immunosuppressive myeloid biology, aiming to enhance immune responses against tumors.OncoResponse, Inc., founded in 2015 and headquartered in Seattle, US, specializes in cancer immunotherapy development. The company has undertaken nine deals, with its most recent funding round occurring on May 1, 2023, during which it raised USD 13.91 mn led by RiverVest Ventures. The total amount raised by the company stands at USD 13.91 mn. Clifford Stocks serves as the CEO.OncoResponse develops novel cancer immunotherapies, focusing on a pipeline of monoclonal antibodies that aim to convert 'cold' tumors into 'hot' ones, thereby improving immune system responses. The company utilizes its clinically validated technology platform to create authentic human antibodies, primarily serving pharmaceutical companies, research institutions, and healthcare providers in North America, Europe, and parts of Asia.OncoResponse generates revenue through strategic partnerships and collaborations within the biotech and pharmaceutical sectors. These partnerships often involve joint development agreements that leverage shared resources, alongside milestone payments and royalties based on the success of developed products. Their offerings focus on enhancing immune activity within the tumor microenvironment and are sold primarily through B2B channels to healthcare providers and research organizations in oncology.In May 2023, OncoResponse raised USD 13.91 mn in venture funding aimed at expanding product development, with participation from several notable investors. The funds will be utilized to advance their pipeline of cancer immunotherapies, targeting specific markets in North America, Europe, and Asia. The company plans to launch new products designed to enhance immunotherapeutic approaches and is committed to expanding its reach within the global oncology market.

## Funding rounds

- Series C, Mar 17, 2021, $41M — ARCH Venture Partners, Canaan Partners, RiverVest Ventures Partners, Magnetar Capital, Qatar Investment Authority, Redmile Group, 3B Future Health Fund, Bering Capital, Yonjin Venture
- Series B, Sep 11, 2018, $19M — ARCH Venture Partners, Canaan Partners, RiverVest Ventures Partners, Alexandria Venture Investments, Qatar Investment Authority, Wright Family Office, Redmile Group, Rice University, 3B Future Health Fund
- Series A, Mar 9, 2017, $3.5M — ARCH Venture Partners, Canaan Partners, Alexandria Venture Investments, The University of Texas MD Anderson Cancer Center, Wright Family Office, GreatPoint Ventures, Rice University, Baxalta Ventures, 3B Future Health Fund
- Series A, Oct 10, 2016, $7M — GreatPoint Ventures, 3B Future Health Fund
- Series A, May 24, 2016, $3M — Baxalta Ventures
- Series A, Sep 30, 2015, $17M — ARCH Venture Partners, Canaan Partners, Alexandria Venture Investments, The University of Texas MD Anderson Cancer Center, Rice University

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B, Series C
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A, Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B
- The University of Texas MD Anderson Cancer Center — Series A
- Rice University — Series A, Series B
- Baxalta Ventures (https://capitalatlas.ai/funds/baxalta-ventures) — Series A
- GreatPoint Ventures (https://capitalatlas.ai/funds/greatpoint-ventures) — Series A
- 3B Future Health Fund (https://capitalatlas.ai/funds/3b-future-health-fund) — Series A, Series B, Series C
- Wright Family Office — Series A, Series B
- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series B, Series C
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series B, Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B, Series C
- Magnetar Capital (https://capitalatlas.ai/funds/magnetar-capital) — Series C
- Bering Capital (https://capitalatlas.ai/funds/bering-capital) — Series C
- Yonjin Venture (https://capitalatlas.ai/funds/yonjin-venture) — Series C